Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Associate Professor
Article types Original article
Language English
Peer review Non peer reviewed
Title Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma.
Journal Formal name:Journal of hepato-biliary-pancreatic sciences
Abbreviation:J Hepatobiliary Pancreat Sci
ISSN code:18686982/18686974
Domestic / ForeginForegin
Volume, Issue, Page 24(11),pp.616-626
Author and coauthor Kaibori Masaki, Kon Masanori, Kitawaki Tomoki, Kawaura Takayuki, Hasegawa Kiyoshi, Kokudo Norihiro, Ariizumi Shunichi, Beppu Toru, Ishizu Hiroyuki, Kubo Shoji, Kamiyama Toshiya, Takamura Hiroyuki, Kobayashi Tsuyoshi, Kim Dong-Sik, Wang Hee Jung, Kim Jong Man, Han Dai Hoon, Park Sang-Jae, Kang Koo Jeong, Hwang Shin, Roh Younghoon, You Young Kyung, Joh Jae-Won, Yamamoto Masakazu
Publication date 2017/11
Summary BACKGROUND:The aim of the present study was to compare the prognostic impact of anatomic resection (AR) versus non-anatomic resection (NAR) on patient survival after resection of a single hepatocellular carcinoma (HCC).METHODS:To control for confounding variable distributions, a 1-to-1 propensity score match was applied to compare the outcomes of AR and NAR. Among 710 patients with a primary, solitary HCC of <5.0 cm in diameter that was resectable by either AR or NAR from 2003 to 2007 in Japan and Korea, 355 patients underwent NAR and 355 underwent AR of at least one section with complete removal of the portal territory containing the tumor.RESULTS:Overall survival (OS) was better in the AR than NAR group (hazard ratio 1.67, 95% confidence interval 1.28-2.19, P < 0.001) while disease-free survival showed no significant difference. Significantly fewer patients in the AR than NAR group developed intrahepatic HCC recurrence and multiple intrahepatic recurrences. Patients with poorly differentiated HCC who underwent AR had improved disease-free survival and OS.CONCLUSIONS:Anatomic resection decreases the risk of tumor recurrence and improves OS in patients with a primary, solitary HCC of <5.0 cm in diameter.
DOI 10.1002/jhbp.502
PMID 28887834